GU cancers steering ahead to new ground vs. weighed down with the past

For the longest time advanced urothelial and bladder carcinomas in particular had few options available to GU oncologists once standard chemotherapy had failed to keep the disease in check.

These days, the field is going through a renaissance with a myriad of targets and therapeutic agents being evaluated as single agents and also in combination strategies.

It’s a whole new world out there, and an exciting one too.

Here we explore some of these new developments and discuss the findings in the context of the broader landscape to uncover fresh insights…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by